BACKGROUND:

Young adults living with perinatally acquired HIV infection (PHIVYAs) are at risk for poor biomedical and behavioral health outcomes. Few studies offer a comprehensive overview of the functioning of this population in young adulthood and the role of HIV.

METHODS:

Data come from the Child and Adolescent Self-Awareness and Health Study, a longitudinal behavioral health cohort study of PHIVYAs and perinatally HIV–exposed but uninfected young adults (PHEUYAs) who are compared on psychiatric and neurocognitive functioning, sexual and substance use behaviors, health and reproductive outcomes, and young adult milestones.

RESULTS:

Overall, 27% of participants met criteria for a psychiatric disorder, including mood (11%), anxiety (22%), and substance use (28%), with no HIV status differences. PHIVYAs performed worse on 2 neurocognitive tests. There were no HIV status differences in condomless sex (41%) or pregnancies (41% women; 38% men). Both groups exhibited similar adult milestones: 67% graduated high school or an equivalent, 19% were in college, and 42% were employed. However, 38% were neither in school or working, 12% reported incarceration, and 16% were ever homeless. Among PHIVYAs, 36% were viremic (>200 copies per mL), and 15% were severely immunocompromised (CD4+ cell count <100 cells per mm3).

CONCLUSIONS:

Many PHIVYAs achieve adult milestones related to school, employment, sexual relationships, and starting families. However, they and PHEUYAs have high rates of psychiatric and substance use disorders and behavioral risks, which can jeopardize long-term health and adult functioning, particularly in the context of HIV. These findings underscore an urgent need to escalate interventions.

What’s Known on This Subject:

Globally, large numbers of individuals with perinatally acquired HIV are aging into adolescence and young adulthood, when they are at increased risk for poor health and behavioral health outcomes, including death, HIV disease progression, mental illness, and neurocognitive deficits.

What This Study Adds:

This is one of the first studies on young adult functioning among individuals with perinatally-acquired HIV, providing new insights into adult transitions, behavioral health, and health outcomes. We demonstrate high rates of behavioral health risks among perinatally HIV–exposed uninfected young adults.

Efforts to prevent mother-to-child HIV transmission in the United States have had remarkable success.1 After decades of scientific discovery, coupled with effective program implementation, there were an estimated 69 new cases of perinatally acquired HIV infection (PHIV) in 2013.2,3 New York City (NYC) reported only 6 new perinatal infections from 2012 to 2015, a decrease from >300 annually in the early 1990s.4 In parallel, treatment advances have resulted in decreased mortality and morbidity and an aging population of adolescents and young adults living with perinatally acquired HIV infection (PHIVYAs).5,8 In NYC, where ∼22% of individuals in the United States with PHIV reside, the majority are now in their 20s.9,10 New concerns have arisen around the health and wellbeing of this population as they reach adulthood11 given that researchers in several studies document an uptick in mortality, opportunistic infections, and hospitalizations as well as poor engagement in care, challenges with antiretroviral treatment (ART) adherence, and low rates of viral suppression (VS) with advancing age.8,12,14 

An array of neurocognitive deficits, mental health problems, and behavioral health risks have been described among PHIVYAs.15,17 Many had delayed ART initiation or suboptimal regimens early in life, resulting in periods of HIV viremia during critical stages of brain development.18,21 Furthermore, most PHIVYAs in the United States are from ethnic minorities and impoverished communities with high rates of substance use, mental health problems, and disparities in educational, vocational, and economic opportunities.22 

From 2003 to 2008, we established a cohort of children with PHIV and perinatally HIV–exposed but uninfected (PHEU) children in NYC to study long-term outcomes of children born to women living with HIV.23,24 We report on and compare behavioral, mental health, biomedical, and adult transition milestone outcomes among PHIVYAs and perinatally HIV–exposed but uninfected young adults (PHEUYAs).

Children with PHIV and PHEU children 9 to 16 years old were recruited into the Child and Adolescent Self-Awareness and Health (CASAH) study from 4 NYC medical centers from 2003 to 2008.25 Inclusion criteria were (1) perinatal HIV exposure, (2) cognitive capacity to complete an interview (excluding severe intellectual deficits), (3) residing with a caregiver who could provide legal consent, and (4) being able to speak English or Spanish. Participants and caregivers completed an assessment battery at enrollment and an 18-month follow-up (FU). The CASAH study received additional funding to add yearly interviews (CASAH 2: 2008–2013; CASAH 3: 2013–2018). In this analysis, we use data from the sixth interview (CASAH 3; FU 5), which was conducted from 2014 to 2017. Caregivers participated in the CASAH and CASAH 2 studies; only young adults (YAs) participated in the CASAH 3 study. At FU 5, a 2- to 3-hour interview consisting of validated measures was administered by trained research assistants. Measures affected by social desirability were assessed by using an audio computer-assisted self-interview (ACASI).

This study was approved by the Columbia University–New York State Psychiatric Institute Institutional Review Board. At FU 5, YAs provided written consent for interviews and collection of data from their medical providers.

Sociodemographic Data

Data were collected at each interview, including from caregivers at enrollment and YAs at FU 5.

Psychiatric and Neurocognitive Functioning

Psychiatric functioning was assessed with the Diagnostic Interview Schedule for Children, a structured diagnostic instrument that asks about symptoms of common psychiatric diagnoses as defined by the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders system.26,28 We examined specific diagnoses within the categories of anxiety, mood, and disruptive behavior disorders and substance use disorders (SUDs).

Neurocognitive executive function was assessed with the Trail Making Test (TMT) and Weschler Adult Intelligence Scale Digit Span subtest.29,30 The TMT is a timed, 2-part measure that requires participants to use visual search, scanning, mental flexibility, and executive function to sequentially connect encircled numbers (TMT A) and encircled numbers and letters (TMT B). The time, in seconds, required to complete TMT A and TMT B is reported. The Weschler Adult Intelligence Scale Digit Span is a 3-part measure of working memory; scores from 3 tests are converted to a Digit Span standard score.

Sexual Risk and Substance Use Behaviors

Participants answered questions via ACASI about (1) lifetime and recent (past 3 months) oral, vaginal, or anal sex; (2) recent condomless vaginal or anal sex; (3) recent types of sex partners; and (4) 30-day use of cigarettes, alcohol, and marijuana. Sexual behavior questions came from the Adolescent Sexual Behavior Assessment31,32; cigarette, alcohol, and marijuana use came from the Monitoring the Future study.33,34 

Reproductive and Other Sexual Health Outcomes

Using the Adolescent Sexual Behavior Assessment and via ACASI, participants reported pregnancy history and pregnancy outcomes, contraception use, and sexually transmitted infections (STIs) in the past year.

YA Milestones

Participants reported on education, employment, incarceration, housing, romantic relationships, current living situation (including financing), and history of homelessness.

PHIV Health Information

HIV RNA viral load (VL) and CD4+ cell counts from the 12 months before FU 5 and current ART regimen were obtained from participants’ health care providers.

Descriptive data (means, SDs, and frequencies) were presented for the total sample and separately by HIV status. Outcomes for PHIVYAs and PHEUYAs were compared by using χ2 tests for categorical variables and t tests for continuous variables. For days hospitalized, a nonparametric test was used (Mann–Whitney) because of a skewed distribution. The CD4+ and VL values obtained closest to the interview were selected, with values dichotomized as CD4+ count <100 and >500 cells per mm3 and VL <50, <200, and >1000 copies per mL. ART regimens were categorized by drug class, number of pills, and frequency of administration. We declared findings to be statistically significant if the corresponding P values were ≤.05. Data were analyzed by using IBM SPSS Statistics 23 (IBM SPSS Statistics, IBM Corporation).

At enrollment, participants included 340 youth, 9 to 16 years old, and their caregivers (206 PHIV and 134 PHEU; Table 1). At FU 5, 248 (151 PHIV and 97 PHEU) YAs completed interviews (Supplemental Fig 1); 1 PHEUYA was excluded from analysis because of HIV seroconversion before FU 5. At enrollment, participants were on average 12.6 years old (SD 2.25), 51% were of female sex, 65% were African American and/or black, and 42% were Latino. Average household income was $27 718, with PHEU youth coming from significantly lower-income homes compared with participants with PHIV ($24 090 vs $30 111; P = .009). Most participants had a female primary caregiver (88%), but PHEU patients were twice as likely to be living with a birth parent (P < .001), and thus, their caregivers were more likely to be living with HIV (P < .001).

TABLE 1

Demographic Characteristics of CASAH Participants at Enrollment and FU 5

Total (N = 340)aPHIV (N = 206)PHEU (N = 134)Pb
Age, y, mean (SD) 12.58 (2.25) 12.70 (2.16) 12.40 (2.37) .218 
Age range, y 9–16 9–16 9–16 — 
Annual household income, $, mean (SD) 27 718 (20 761) 30 111 (21 687) 24 090 (18 783) .009 
Annual household income range, $ 0–126 000 0–121 200 0–126 000 — 
Female sex, n (%) 172 (51) 104 (51) 68 (51) .963 
African American and/or black race, n (%) 221 (65) 135 (66) 86 (64) .798 
Latino ethnicity, n (%) 142 (42) 79 (38) 63 (47) .113 
Caregiver type, n (%)     
 Biological parent 167 (49) 73 (35) 94 (70) <.001 
 Relative 80 (24) 59 (29) 21 (16)  
 Nonrelative 93 (27) 74 (36) 19 (14)  
Caregiver is of female sex, n (%) 298 (88) 179 (87) 119 (89) .600 
Caregiver HIV status, with PHIV, n (%) 150 (46) 61 (31) 89 (69) <.001 
  Total (N = 248) PHIV (N = 151) PHEU (N = 97)  
Age, y, mean (SD) 22.38 (2.68) 22.79 (2.63) 21.72 (2.65) .002 
Age range, y 18–28 18–28 18–28 — 
Female sex, n (%) 133 (54) 83 (55) 50 (52) .598 
African American and/or black race, n (%) 170 (69) 106 (70) 64 (66) .485 
Latino ethnicity, n (%) 124 (50) 73 (48) 51 (53) .515 
Household enrolled in housing assistance program, n (%) 114 (48) 81 (56) 33 (36) .002 
Disability and/or SSI, n (%) 41 (17) 38 (25) 3 (3) <.001 
Public assistance and/or HASA, n (%) 61 (25) 58 (38) 3 (3) <.001 
Food stamps and/or WIC, n (%) 96 (39) 79 (52) 17 (18) <.001 
Medicaid, n (%) 204 (82) 132 (87) 72 (74) .008 
Medicare, n (%) 10 (4) 8 (5) 2 (2) .206 
Private only, n (%) 14 (6) 7 (5) 7 (7) .390 
Other only, n (%) 14 (6) 8 (5) 6 (6) .768 
None, n (%) 9 (4) 1 (1) 8 (8) .002 
Total (N = 340)aPHIV (N = 206)PHEU (N = 134)Pb
Age, y, mean (SD) 12.58 (2.25) 12.70 (2.16) 12.40 (2.37) .218 
Age range, y 9–16 9–16 9–16 — 
Annual household income, $, mean (SD) 27 718 (20 761) 30 111 (21 687) 24 090 (18 783) .009 
Annual household income range, $ 0–126 000 0–121 200 0–126 000 — 
Female sex, n (%) 172 (51) 104 (51) 68 (51) .963 
African American and/or black race, n (%) 221 (65) 135 (66) 86 (64) .798 
Latino ethnicity, n (%) 142 (42) 79 (38) 63 (47) .113 
Caregiver type, n (%)     
 Biological parent 167 (49) 73 (35) 94 (70) <.001 
 Relative 80 (24) 59 (29) 21 (16)  
 Nonrelative 93 (27) 74 (36) 19 (14)  
Caregiver is of female sex, n (%) 298 (88) 179 (87) 119 (89) .600 
Caregiver HIV status, with PHIV, n (%) 150 (46) 61 (31) 89 (69) <.001 
  Total (N = 248) PHIV (N = 151) PHEU (N = 97)  
Age, y, mean (SD) 22.38 (2.68) 22.79 (2.63) 21.72 (2.65) .002 
Age range, y 18–28 18–28 18–28 — 
Female sex, n (%) 133 (54) 83 (55) 50 (52) .598 
African American and/or black race, n (%) 170 (69) 106 (70) 64 (66) .485 
Latino ethnicity, n (%) 124 (50) 73 (48) 51 (53) .515 
Household enrolled in housing assistance program, n (%) 114 (48) 81 (56) 33 (36) .002 
Disability and/or SSI, n (%) 41 (17) 38 (25) 3 (3) <.001 
Public assistance and/or HASA, n (%) 61 (25) 58 (38) 3 (3) <.001 
Food stamps and/or WIC, n (%) 96 (39) 79 (52) 17 (18) <.001 
Medicaid, n (%) 204 (82) 132 (87) 72 (74) .008 
Medicare, n (%) 10 (4) 8 (5) 2 (2) .206 
Private only, n (%) 14 (6) 7 (5) 7 (7) .390 
Other only, n (%) 14 (6) 8 (5) 6 (6) .768 
None, n (%) 9 (4) 1 (1) 8 (8) .002 

HASA, HIV/AIDS Service Administration; SSI, Social Security Insurance; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children; —, not applicable.

a

Some variables had missing data; only household income was missing for >15 (15 PHIV and 8 PHEU) participants. Percentages are based on those without missing data.

b

P values are from t tests (continuous variables) or χ2 tests (dichotomous and/or categorical variables).

At FU 5, participant ages ranged from 18 to 28 years, with PHIVYAs being older than PHEUYAs (mean age 22.8 vs 21.7 years; P = .002). Between enrollment and FU 5, participants completed a mean of 5 interviews (range 1–6). Eleven deaths were reported, 10 among those with PHIV (4 attributed to HIV, 1 to systemic lupus erythematosus, and 5 unknown) and 1 PHEU patient (from an accident). There were no significant differences in enrollment characteristics (eg, age, race, sex, income, HIV status, and caregiver type) among YAs retained versus not retained for FU 5. However, YAs without a psychiatric disorder in both groups were more likely to be lost to FU, although the difference was only significant for PHEUYAs (data not shown).

At FU 5, significantly more PHIVYAs received housing assistance (P = .002), public assistance (P < .001), food stamps (P < .001), and disability payments (P < .001) compared with PHEUYAs. Most had health insurance, with more PHIVYAs receiving Medicaid (P = .008) and fewer PHIVYAs than PHEUYAs being uninsured (P = .002). Significantly more PHIVYAs than PHEUYAs reported deaths of birth parents (61% vs 35%; P < .001) or other caregivers (eg, grandparents; 25% vs 13%; P = .033).

Laboratory data were available for 126 of 151 PHIVYAs. Mean CD4+ was 491 cells per mm3 (range 2–1430 cells per mm3); 44% had a CD4+ of >500 cells per mm3, 20% had a CD4+ of <200 cells per mm3, and 15% had a CD4+ of <100 cells per mm3 (Table 2). Approximately two-thirds (64%) were virally suppressed to <200 copies per mL (range undetectable to >2 000 000 copies per mL; mean 2.4 log10 copies per mL; SD 1.66). ART regimen data were available for 132 of 151 PHIVYAs, including 8 who were not prescribed ART. Among 124 who were prescribed ART, 67% received a 1-drug– or 2-drug–class regimen, and 31% received a 3-class combination. Fifty-eight percent received a regimen that included a boosted protease inhibitor (bPI), and half (50%) received an integrase inhibitor. Most PHIVYAs (87%) were on once-daily regimens, but only 33% took a single fixed-dose combination pill; 34% were taking 4 or more pills daily.

TABLE 2

Health Status and ART of PHIVYAs and PHEUYAs

Total (N = 248)PHIV (N = 151)PHEU (N = 97)χ2 (df)aP
Self-reported health conditions, n (%)b      
 Asthma or allergies 115 (46) 74 (49) 41 (42) 1.08 (1) .299 
 Arthritis 13 (5) 6 (4) 7 (7) 1.25 (1) .263 
 Diseases of the heart 10 (4) 7 (5) 3 (3) 0.38 (1) .540 
 Hepatitis 4 (2) 4 (3) 0 (0) 2.61 (1) .106c 
 Diabetes 3 (1) 3 (2) 0 (0) 1.95 (1) .163c 
 Cancer 2 (1) 2 (1) 0 (0) 1.30 (1) .255c 
 Inpatient medical care (past y) 47 (19) 33 (22) 14 (14) 2.12 (1) .146 
 No. d in hospital (past y), mean (SD); range 2.42 (11.75); 1–120 3.62 (14.89); 1–120 0.57 (1.84); 1–10 −1.64d .100 
 Any nonpsychopharmocologic mental health services 82 (33) 63 (42) 19 (20) 13.07 (1) <.001 
 Psychotropic mental health treatment 30 (12) 24 (16) 6 (6) 5.24 (1) .022 
 Drug or alcohol treatment 4 (2) 2 (1) 2 (2) 0.20 (1) .653c 
HIV disease status (N = 126)      
 CD4+ <100 cells per mm3, n (%)b — 19 (15) — — — 
 CD4+ <200 cells per mm3, n (%)b — 26 (20) — — — 
 CD4+ >500 cells per mm3, n (%)b — 56 (44) — — — 
 CD4+ cells per mm3, mean (range) — 491.42 (2–1430) — — — 
 VL <50 copies per mL, n (%)b — 65 (52) — — — 
 VL <200 copies per mL, n (%)b — 80 (64) — — — 
 VL >1000 copies per mL, n (%)b — 40 (32) — — — 
 VL log copies per mL, mean (median)  — 2.41 (1.66) — — — 
ART regimens (N = 132), n (%)b      
 Not prescribed ART — 8 (6) — — — 
 No. drug classes (N = 124) —  — — — 
  ≤2 — 83 (67) — — — 
  3 — 38 (31) — — — 
  4 — 3 (2) — — — 
 Most common drug class combinations      
  NRTI + bPI — 26 (21) — — — 
  NRTI + NNRTI — 22 (18) — — — 
  NRTI + bPI + INSI — 21 (17) — — — 
  NRTI + bINSI and/or INSI — 16 (13) — — — 
  INSI-containing regimen — 62 (50) — — — 
  bPI-containing regimen — 72 (58) — — — 
 No. pills per d (N = 118)      
  1 — 39 (33) — — — 
  2 — 10 (8) — — — 
  3 — 29 (25) — — — 
  ≥4 — 40 (34) — — — 
 Dosing regimen (N = 115) —  — — — 
  Once daily — 100 (87) — — — 
  Twice daily — 15 (13) — — — 
Total (N = 248)PHIV (N = 151)PHEU (N = 97)χ2 (df)aP
Self-reported health conditions, n (%)b      
 Asthma or allergies 115 (46) 74 (49) 41 (42) 1.08 (1) .299 
 Arthritis 13 (5) 6 (4) 7 (7) 1.25 (1) .263 
 Diseases of the heart 10 (4) 7 (5) 3 (3) 0.38 (1) .540 
 Hepatitis 4 (2) 4 (3) 0 (0) 2.61 (1) .106c 
 Diabetes 3 (1) 3 (2) 0 (0) 1.95 (1) .163c 
 Cancer 2 (1) 2 (1) 0 (0) 1.30 (1) .255c 
 Inpatient medical care (past y) 47 (19) 33 (22) 14 (14) 2.12 (1) .146 
 No. d in hospital (past y), mean (SD); range 2.42 (11.75); 1–120 3.62 (14.89); 1–120 0.57 (1.84); 1–10 −1.64d .100 
 Any nonpsychopharmocologic mental health services 82 (33) 63 (42) 19 (20) 13.07 (1) <.001 
 Psychotropic mental health treatment 30 (12) 24 (16) 6 (6) 5.24 (1) .022 
 Drug or alcohol treatment 4 (2) 2 (1) 2 (2) 0.20 (1) .653c 
HIV disease status (N = 126)      
 CD4+ <100 cells per mm3, n (%)b — 19 (15) — — — 
 CD4+ <200 cells per mm3, n (%)b — 26 (20) — — — 
 CD4+ >500 cells per mm3, n (%)b — 56 (44) — — — 
 CD4+ cells per mm3, mean (range) — 491.42 (2–1430) — — — 
 VL <50 copies per mL, n (%)b — 65 (52) — — — 
 VL <200 copies per mL, n (%)b — 80 (64) — — — 
 VL >1000 copies per mL, n (%)b — 40 (32) — — — 
 VL log copies per mL, mean (median)  — 2.41 (1.66) — — — 
ART regimens (N = 132), n (%)b      
 Not prescribed ART — 8 (6) — — — 
 No. drug classes (N = 124) —  — — — 
  ≤2 — 83 (67) — — — 
  3 — 38 (31) — — — 
  4 — 3 (2) — — — 
 Most common drug class combinations      
  NRTI + bPI — 26 (21) — — — 
  NRTI + NNRTI — 22 (18) — — — 
  NRTI + bPI + INSI — 21 (17) — — — 
  NRTI + bINSI and/or INSI — 16 (13) — — — 
  INSI-containing regimen — 62 (50) — — — 
  bPI-containing regimen — 72 (58) — — — 
 No. pills per d (N = 118)      
  1 — 39 (33) — — — 
  2 — 10 (8) — — — 
  3 — 29 (25) — — — 
  ≥4 — 40 (34) — — — 
 Dosing regimen (N = 115) —  — — — 
  Once daily — 100 (87) — — — 
  Twice daily — 15 (13) — — — 

bINSI, boosted integrase strand transfer inhibitor; df, degrees of freedom; INSI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; —, not applicable.

a

Statistics shown are χ2 and df from χ2 tests (dichotomous variables).

b

Percentages are based on those without missing data.

c

Unreliable test statistic because of low N meeting criteria.

d

z score from the Mann–Whitney test.

Asthma and allergies were the most prevalent health conditions, with no significant HIV status differences seen (Table 2). In the past year, 19% of participants received inpatient medical care (22% PHIV; 14% PHEU), with PHIVYAs averaging 3.6 hospital days (range 1–120 days) compared with <1 day reported by PHEUYAs. Significantly more PHIVYAs than PHEUYAs (1) were prescribed psychotropic medication treatments (16% vs 6%; P = .022) and/or (2) received any nonpsychopharmacologic mental health services (42% vs 20%; P < .001). Few (2 per group) reported substance use treatment.

There were few HIV status differences in psychiatric disorder rates; 27% of all participants met criteria for any non-SUD psychiatric disorder (Table 3). Anxiety disorders (22%; particularly generalized anxiety disorder) and mood disorders (11%; particularly major depression) were the most prevalent.

TABLE 3

Psychiatric and Neurocognitive Functioning of PHIVYAs and PHEUYAs

Total (N = 248)PHIV (N = 151)PHEU (N = 97)Pa
Any psychiatric disorder, excluding substance use, n (%)b,c 64 (27) 38 (26) 26 (27) .943 
Any mood disorder, n (%)b,c 26 (11) 16 (11) 10 (10) .844 
 Major depression 20 (8) 12 (9) 8 (8) .956 
 Hypomania 8 (3) 4 (3) 4 (4) .574d 
Any disruptive behavior disorder, n (%)c 7 (3) 2 (1) 5 (5) .088d 
 ADHD 5 (2) 1 (1) 4 (4) .068d 
 Conduct disorder 2 (1) 1 (1) 1 (1) .778d 
Any anxiety disorder, n (%)b,c 53 (22) 31 (22) 22 (23) .832 
 Agoraphobia 25 (10) 16 (11) 9 (9) .647 
 Generalized anxietyb 29 (12) 16 (11) 13 (13) .592 
 Panic 5 (2) 4 (3) 1 (1) .351d 
 PTSD 13 (5) 7 (5) 6 (6) .655 
 Social phobia 12 (5) 4 (3) 8 (8) .056 
Any SUD, n (%)b,c 66 (28) 36 (25) 30 (31) .327 
 Alcohol 35 (15) 19 (13) 16 (17) .490 
 Marijuana 47 (20) 27 (19) 20 (21) .739 
Smoked cigarettes in past 30 d, n (%)c 69 (28) 42 (28) 27 (28) .977 
Had alcohol in past 30 d, n (%)c 154 (63) 93 (63) 61 (64) .911 
Been drunk in past 30 d, n (%)c 77 (35) 42 (32) 35 (40) .226 
Used marijuana in past 30 d, n (%)c 115 (47) 70 (47) 45 (47) .987 
Used marijuana daily in past 30 d, n (%)c 58 (24) 34 (23) 24 (25) .695 
TMT A, mean (SD); range 26.29 (11.44); 12–127 28.26 (13.24); 12–127 23.17 (6.79); 12–47 <.001 
TMT B, mean (SD); range 73.05 (45.78); 21–427 76.53 (49.05); 27–427 67.56 (39.72); 21–255 .155 
Digit span standard score, mean (SD); range 8.00 (2.73); 1–17 7.62 (2.86); 1–17 8.59 (2.40); 3–15 .009 
Total (N = 248)PHIV (N = 151)PHEU (N = 97)Pa
Any psychiatric disorder, excluding substance use, n (%)b,c 64 (27) 38 (26) 26 (27) .943 
Any mood disorder, n (%)b,c 26 (11) 16 (11) 10 (10) .844 
 Major depression 20 (8) 12 (9) 8 (8) .956 
 Hypomania 8 (3) 4 (3) 4 (4) .574d 
Any disruptive behavior disorder, n (%)c 7 (3) 2 (1) 5 (5) .088d 
 ADHD 5 (2) 1 (1) 4 (4) .068d 
 Conduct disorder 2 (1) 1 (1) 1 (1) .778d 
Any anxiety disorder, n (%)b,c 53 (22) 31 (22) 22 (23) .832 
 Agoraphobia 25 (10) 16 (11) 9 (9) .647 
 Generalized anxietyb 29 (12) 16 (11) 13 (13) .592 
 Panic 5 (2) 4 (3) 1 (1) .351d 
 PTSD 13 (5) 7 (5) 6 (6) .655 
 Social phobia 12 (5) 4 (3) 8 (8) .056 
Any SUD, n (%)b,c 66 (28) 36 (25) 30 (31) .327 
 Alcohol 35 (15) 19 (13) 16 (17) .490 
 Marijuana 47 (20) 27 (19) 20 (21) .739 
Smoked cigarettes in past 30 d, n (%)c 69 (28) 42 (28) 27 (28) .977 
Had alcohol in past 30 d, n (%)c 154 (63) 93 (63) 61 (64) .911 
Been drunk in past 30 d, n (%)c 77 (35) 42 (32) 35 (40) .226 
Used marijuana in past 30 d, n (%)c 115 (47) 70 (47) 45 (47) .987 
Used marijuana daily in past 30 d, n (%)c 58 (24) 34 (23) 24 (25) .695 
TMT A, mean (SD); range 26.29 (11.44); 12–127 28.26 (13.24); 12–127 23.17 (6.79); 12–47 <.001 
TMT B, mean (SD); range 73.05 (45.78); 21–427 76.53 (49.05); 27–427 67.56 (39.72); 21–255 .155 
Digit span standard score, mean (SD); range 8.00 (2.73); 1–17 7.62 (2.86); 1–17 8.59 (2.40); 3–15 .009 

ADHD, attention-deficit/hyperactivity disorder; PTSD, posttraumatic stress disorder.

a

P values are from χ2 tests (dichotomous variables) or t tests (continuous variables).

b

Diagnoses with ≤2 cases (dysthymia, mania, specific phobia, and other SUD) are excluded.

c

Percentages are based on those without missing data.

d

Unreliable test statistic because of low N meeting criteria.

There were no significant HIV status differences for substance use or SUD (Table 3). Overall, 28% reported cigarette use, 63% reported alcohol use, and 47% reported marijuana use in the past 30 days. Nearly one-quarter (24%) reported daily marijuana use, and 35% reported being drunk in the past 30 days. High rates of YAs met SUD criteria (28%), with marijuana (20%) and alcohol (15%) use disorders being the most prevalent. Finally, 10% of participants met criteria for both a psychiatric disorder and SUD (data not shown).

Neurocognitive function differed by HIV status (Table 3). They required a significantly longer time to complete TMT A (28.3 vs 23.2 seconds; P < .001) and obtained significantly lower Digit Span standard scores (7.6 vs 8.6; P = .009); there were no HIV group differences on TMT B.

We found no significant HIV status differences in sexual behaviors (Table 4). The majority had initiated sex (93%); in the past 3 months, 63% had vaginal, 12% had anal, and 41% had condomless sex. In the past 3 months, 60% reported sex with opposite-sex partners only, 12% had at least 1 same-sex partner, and 28% reported no partnered sex.

TABLE 4

Reproductive and Sexual Health Outcomes Reported by PHIVYAs and PHEUYAs

Total (N = 248)PHIV (N = 151)PHEU (N = 97)Pa
N (%b)N (%b)N (%b)
Sex     
 Ever had sex (oral, vaginal, and/or anal) 222 (93) 136 (93) 86 (92) .633 
 Vaginal sex, past 3 mo 152 (63) 88 (60) 64 (67) .214 
 Anal sex, past 3 mo 28 (12) 16 (11) 12 (13) .651 
 Vaginal and/or anal sex, past 3 mo 153 (62) 89 (60) 64 (67) .274 
 Condomless vaginal and/or anal sex, past 3 mo 101 (41) 56 (38) 45 (47) .149 
 Sexualc partners, past 3 mo     
  None 66 (28) 44 (30) 22 (23) .365 
  Opposite-sex only 144 (60) 84 (58) 60 (64)  
  Same-sex only 17 (7) 12 (8) 5 (5)  
  Same- and opposite-sex partners 13 (5) 6 (4) 7 (7)  
Female responses     
 Ever been pregnant 53 (41) 31 (39) 22 (45) .491 
 Any pregnancy ending in live birth 30 (23) 20 (25) 10 (20) .549 
 Any pregnancy ending in miscarriage 20 (16) 10 (13) 10 (20) .228 
 Any pregnancy ending in abortion 24 (19) 11 (14) 13 (27) .070 
 Currently pregnant 3 (2) 3 (4) 0 (0) .170d 
 Currently living with child 27 (20) 18 (22) 9 (18) .609 
Male responses     
 Ever gotten someone pregnant 43 (38) 25 (37) 18 (38) .915 
 Any pregnancy ending in live birth 20 (18) 16 (24) 4 (9) .034 
 Any pregnancy ending in miscarriage 13 (11) 8 (12) 5 (11) .830 
 Any pregnancy ending in abortion 16 (14) 7 (10) 9 (19) .188 
 Mother currently pregnant 4 (4) 1 (2) 3 (6) .162d 
 Currently living with child 7 (6) 7 (10) 0 (0) .023d 
Methods of Birth Controle     
 Male condom, ever 189 (91) 118 (92) 71 (90) .566 
  Past y 156 (76) 99 (78) 57 (72) .345 
 Female condom, ever 36 (18) 24 (19) 12 (15) .496 
  Past y 25 (12) 17 (13) 8 (10) .486 
 Male condom 135 (70) 85 (71) 50 (68) .569 
 Withdrawal 93 (49) 50 (42) 43 (59) .026 
 Oral sex instead of vaginal 40 (21) 21 (18) 19 (26) .184 
 Oral contraceptive 37 (19) 17 (15) 20 (26) .042 
 Emergency contraception 27 (14) 12 (10) 15 (20) .058 
 Depo Provera 26 (14) 19 (16) 7 (9) .166 
 Rhythm 14 (7) 7 (6) 7 (10) .364 
 Female condom 13 (7) 10 (8) 3 (4) .241 
 IUD 13 (7) 7 (6) 6 (8) .538 
Sexually Transmitted Infections (STIs)f     
 Any STI 29 (12) 26 (17) 3 (3) .001 
Chlamydia 13 (5) 11 (7) 2 (2) .076 
 HPV 10 (4) 9 (6) 1 (1) .052 
 Genital herpes 9 (4) 9 (6) 0 (0) .013 
Total (N = 248)PHIV (N = 151)PHEU (N = 97)Pa
N (%b)N (%b)N (%b)
Sex     
 Ever had sex (oral, vaginal, and/or anal) 222 (93) 136 (93) 86 (92) .633 
 Vaginal sex, past 3 mo 152 (63) 88 (60) 64 (67) .214 
 Anal sex, past 3 mo 28 (12) 16 (11) 12 (13) .651 
 Vaginal and/or anal sex, past 3 mo 153 (62) 89 (60) 64 (67) .274 
 Condomless vaginal and/or anal sex, past 3 mo 101 (41) 56 (38) 45 (47) .149 
 Sexualc partners, past 3 mo     
  None 66 (28) 44 (30) 22 (23) .365 
  Opposite-sex only 144 (60) 84 (58) 60 (64)  
  Same-sex only 17 (7) 12 (8) 5 (5)  
  Same- and opposite-sex partners 13 (5) 6 (4) 7 (7)  
Female responses     
 Ever been pregnant 53 (41) 31 (39) 22 (45) .491 
 Any pregnancy ending in live birth 30 (23) 20 (25) 10 (20) .549 
 Any pregnancy ending in miscarriage 20 (16) 10 (13) 10 (20) .228 
 Any pregnancy ending in abortion 24 (19) 11 (14) 13 (27) .070 
 Currently pregnant 3 (2) 3 (4) 0 (0) .170d 
 Currently living with child 27 (20) 18 (22) 9 (18) .609 
Male responses     
 Ever gotten someone pregnant 43 (38) 25 (37) 18 (38) .915 
 Any pregnancy ending in live birth 20 (18) 16 (24) 4 (9) .034 
 Any pregnancy ending in miscarriage 13 (11) 8 (12) 5 (11) .830 
 Any pregnancy ending in abortion 16 (14) 7 (10) 9 (19) .188 
 Mother currently pregnant 4 (4) 1 (2) 3 (6) .162d 
 Currently living with child 7 (6) 7 (10) 0 (0) .023d 
Methods of Birth Controle     
 Male condom, ever 189 (91) 118 (92) 71 (90) .566 
  Past y 156 (76) 99 (78) 57 (72) .345 
 Female condom, ever 36 (18) 24 (19) 12 (15) .496 
  Past y 25 (12) 17 (13) 8 (10) .486 
 Male condom 135 (70) 85 (71) 50 (68) .569 
 Withdrawal 93 (49) 50 (42) 43 (59) .026 
 Oral sex instead of vaginal 40 (21) 21 (18) 19 (26) .184 
 Oral contraceptive 37 (19) 17 (15) 20 (26) .042 
 Emergency contraception 27 (14) 12 (10) 15 (20) .058 
 Depo Provera 26 (14) 19 (16) 7 (9) .166 
 Rhythm 14 (7) 7 (6) 7 (10) .364 
 Female condom 13 (7) 10 (8) 3 (4) .241 
 IUD 13 (7) 7 (6) 6 (8) .538 
Sexually Transmitted Infections (STIs)f     
 Any STI 29 (12) 26 (17) 3 (3) .001 
Chlamydia 13 (5) 11 (7) 2 (2) .076 
 HPV 10 (4) 9 (6) 1 (1) .052 
 Genital herpes 9 (4) 9 (6) 0 (0) .013 

HPV, human papillomavirus; IUD, intrauterine device.

a

P values are from χ2 tests.

b

Percentages are based on those without missing data.

c

Sex includes vaginal, oral, or anal (opposite sex); oral or anal (same-sex, male); and oral (same-sex, female).

d

Unreliable test statistic because of low N meeting criteria.

e

Methods with N <10 are excluded.

f

STIs with N <5 are excluded.

Among women, 41% reported lifetime pregnancy, 23% had a pregnancy end in a live birth, and 20% were currently living with their child (Table 4). Among men, 38% reported lifetime pregnancy in a partner, 18% reported a pregnancy ending in a live birth, and 6% were living with a child. There were few HIV group differences in contraceptive use and STIs. Almost all sexually active participants reported lifetime (91%) and past-year (76%) use of condoms. Male condoms were the most common birth control method used in the past year (70%); other methods included withdrawal (49%), having oral instead of vaginal sex (21%), and oral contraceptives (19%). Methods used varied by HIV status, with more PHEUYAs reporting withdrawal (P = .026) and oral contraceptive use (P = .042).

There were no statistically significant HIV status differences in educational achievement or employment status (Table 5). Sixty-seven percent of YAs had graduated high school (HS), obtained a general equivalency diploma, or were on track to graduate HS, and 19% attended college. Less than half were working (42%), but 62% were either working or in school. Twelve percent of YAs reported ever being incarcerated, 2% in the past year, with no HIV status differences.

TABLE 5

Adult Milestones Reported by PHIVYAs and PHEUYAs

Total (N = 248)PHIV (N = 151)PHEU (N = 97)Pa
Highest degree earned, n (%)b     
Less than HS degree, n (%)b 61 (25) 34 (23) 27 (28) .700 
HS diploma or GED,cn (%)b 166 (67) 103 (68) 63 (65)  
Associate’s degree, n (%)b 10 (4) 6 (4) 4 (4)  
Bachelor’s degree, n (%)b 11 (4) 8 (5) 3 (3)  
In school, n (%)b 75 (30) 40 (27) 35 (36) .108 
Currently in college, n (%)b 48 (19) 24 (16) 24 (25) .085 
Currently employed, n (%)b 103 (42) 59 (39) 44 (45) .327 
Employed and/or in school, n (%)b 154 (62) 88 (58) 66 (68) .122 
Ever incarcerated, n (%)b 29 (12) 15 (10) 14 (14) .282 
Incarcerated, past y, n (%)b 5 (2) 2 (1) 3 (3) .334d 
Living rent free with family and/or friends, n (%)b 124 (50) 58 (38) 66 (68) <.001e 
Renting a room and/or apartment with others or paying rent to family, n (%)b 106 (43) 81 (54) 25 (26)  
College dormitory, n (%)b 8 (3) 3 (2) 5 (5) — 
Homeless, n (%)b 2 (1) 1 (1) 1 (1) — 
Specialty HIV housing or other, n (%)b 8 (3) 8 (5) 0 (0) — 
Household size,f mean (SD) 3.47 (2.21) 3.25 (2.51) 3.80 (1.60) .037 
Ever homeless, n (%)b 39 (16) 25 (17); 7 in past y 14 (15); 7 in past y .663 
Ever in a romantic relationship, n (%)b 231 (93) 142 (94) 89 (92) .487 
Currently in a relationship, n (%)b 120 (48) 68 (45) 52 (54) .187 
Marital status, n (%)b     
 Married 6 (2) 2 (1) 4 (4) .155g 
 Engaged 8 (3) 4 (3) 4 (4)  
 Separated and/or divorced 0 (0) 0 (0) 0 (0)  
 Widowed 0 (0) 0 (0) 0 (0)  
 Single 234 (94) 145 (96) 89 (92)  
Total (N = 248)PHIV (N = 151)PHEU (N = 97)Pa
Highest degree earned, n (%)b     
Less than HS degree, n (%)b 61 (25) 34 (23) 27 (28) .700 
HS diploma or GED,cn (%)b 166 (67) 103 (68) 63 (65)  
Associate’s degree, n (%)b 10 (4) 6 (4) 4 (4)  
Bachelor’s degree, n (%)b 11 (4) 8 (5) 3 (3)  
In school, n (%)b 75 (30) 40 (27) 35 (36) .108 
Currently in college, n (%)b 48 (19) 24 (16) 24 (25) .085 
Currently employed, n (%)b 103 (42) 59 (39) 44 (45) .327 
Employed and/or in school, n (%)b 154 (62) 88 (58) 66 (68) .122 
Ever incarcerated, n (%)b 29 (12) 15 (10) 14 (14) .282 
Incarcerated, past y, n (%)b 5 (2) 2 (1) 3 (3) .334d 
Living rent free with family and/or friends, n (%)b 124 (50) 58 (38) 66 (68) <.001e 
Renting a room and/or apartment with others or paying rent to family, n (%)b 106 (43) 81 (54) 25 (26)  
College dormitory, n (%)b 8 (3) 3 (2) 5 (5) — 
Homeless, n (%)b 2 (1) 1 (1) 1 (1) — 
Specialty HIV housing or other, n (%)b 8 (3) 8 (5) 0 (0) — 
Household size,f mean (SD) 3.47 (2.21) 3.25 (2.51) 3.80 (1.60) .037 
Ever homeless, n (%)b 39 (16) 25 (17); 7 in past y 14 (15); 7 in past y .663 
Ever in a romantic relationship, n (%)b 231 (93) 142 (94) 89 (92) .487 
Currently in a relationship, n (%)b 120 (48) 68 (45) 52 (54) .187 
Marital status, n (%)b     
 Married 6 (2) 2 (1) 4 (4) .155g 
 Engaged 8 (3) 4 (3) 4 (4)  
 Separated and/or divorced 0 (0) 0 (0) 0 (0)  
 Widowed 0 (0) 0 (0) 0 (0)  
 Single 234 (94) 145 (96) 89 (92)  

GED, general equivalency diploma; —, not applicable.

a

P values are from χ2 tests (dichotomous and/or categorical variables) or t tests (household size).

b

Percentages are based on those without missing data.

c

Inclusive of 18- and 19-y-old students in their senior y of HS.

d

Unreliable test statistic because of low N meeting criteria.

e

Two statistical tests (lives rent free versus others; renting a room versus others; both P < .001).

f

Excluding dormitory, homeless, and other.

g

χ2 test used to compare married and/or engaged versus single.

Almost all participants had ever been in a romantic relationship (93%), with nearly half (48%) being currently in one. The vast majority (94%) were single and never married.

Significant HIV status differences were found in living situations: more PHEUYAs were living rent free with family or friends compared with PHIVYAs (68% vs 38%; P < .001), whereas PHIVYAs were more likely to be renting a room or apartment or contributing rent (54% PHIV vs 26% PHEU; P < .001), likely because of HIV-related subsidies and/or housing assistance. Overall, 16% of the cohort had ever been homeless, with no HIV status differences.

Using data from CASAH, 1 of the first and largest behavioral health studies in the United States that includes a highly representative cohort of PHIVYAs from NYC and a comparison cohort of PHEUYAs from similar backgrounds, we report on long-term behavioral, psychosocial, and biomedical outcomes among individuals who were born at the height of the perinatal HIV epidemic in United States. We found that despite the challenges of living with a chronic, stigmatized illness, behavioral health and psychosocial outcomes among PHIVYAs appear to be comparable to those of PHEUYAs who grew up in similar circumstances. As they reach adulthood, many PHIVYAs are achieving normal adult milestones, completing school, securing employment, engaging in relationships, and starting families. At the same time, both PHIVYAs and PHEUYAs have high rates of psychiatric disorders and SUDs, incarceration, homelessness, and high-risk sexual behaviors at rates that are similar to those of YAs living in poor, urban communities throughout the United States.35,37 

The biomedical health outcomes of PHIVYAs were mixed. Ten PHIVYAs were known to have died since enrollment, with only 1 PHEUYA death occurring. Furthermore, more than one-third of the PHIVYAs with available data had viremia (>200 copies per mL), and 15% were severely immunocompromised, putting them at high risk for disease progression and HIV transmission to sexual partners. An analysis of youth with PHIV in the United States revealed that the proportion of time spent viremic and with a low CD4+ cell count is substantially higher among adolescents with PHIV and PHIVYAs compared with 7- to 12-year-old children with PHIV.8 Low rates of VS (45.9%) have been reported among PHIVYAs on ART at US adolescent centers.13 In NYC, VS rates among PHIVYAs were lower compared with nonperinatally HIV–infected YAs (61% vs 72%).10 In our cohort, among those on treatment, most received potent regimens with bPIs and/or integrase inhibitors given once daily. Nonetheless, we know that many PHIVYAs have had periods of inadequate adherence,14,38,39 harbor a multidrug-resistant virus,40 and are subject to a variety of risk factors, including high rates of psychiatric disorders23,41,42 that put them at continued risk for suboptimal adherence, viremia, and poor health outcomes.

Unique to our study, we used a well-validated diagnostic psychiatric interview, the Diagnostic Interview Schedule for Children, to evaluate psychiatric disorders, whereas researchers in most studies use symptom checklists. We found that 27% of YAs had a psychiatric disorder, with no significant group differences seen. Rates of psychiatric disorders were similar to or slightly greater than in cohorts of uninfected YAs in the United States.43,45 Importantly, rates of depression are similar to those reported for African American and/or black, Latino, and low-income YAs (6%–10%) in the United States.46 Rates of anxiety disorders are also consistent with those reported among college-aged individuals.47 That being said, given that PHIVYAs were more likely to have received mental health treatment, including psychotropic medications, it is possible that they may be at greater risk, but treatment has improved their mental health to the level of the PHEUYAs who have less access to mental health services.

Both groups reported high rates of cigarette, alcohol, and marijuana use, and 28% met diagnostic criteria for SUD, which is notably higher than what has been reported from a national study of YAs, in which 21% of white, 17% of Hispanic, and 16% of black 18- to 24-year-old respondents met criteria for drug or alcohol dependence or abuse.48,49 Although there were no group differences in substance use generally, given that most PHIVYAs were engaged in long-term comprehensive HIV care and had higher rates of mental health treatment, it is of concern that rates were not lower.50,51 

CASAH participants performed below average on tests of executive function and planning ability, with lower performance being among PHIVYAs than among PHEUYAs. Differences in executive function between patients with PHIV and PHEU patients have been attributed to the cumulative impact of late ART initiation with suboptimal regimens, periods of incomplete adherence and sustained viremia, and both the direct and indirect impact of HIV on the central nervous system.52,53 Compromised neurocognitive function may exacerbate difficulties with transitioning to adulthood. Cognitive remediation interventions may be helpful, as has been demonstrated in adults with other brain insults.54 

Almost all participants reported having engaged in sexual intercourse, 41% of women reported a pregnancy, and 38% of men reported a partner’s pregnancy, with no notable HIV group differences seen. Pregnancy outcomes were similar (miscarriage, abortion, and live birth) for women with PHIV and PHEU women. Researchers in several cohort studies have reported on pregnancies among PHIVYAs, but we are the first to demonstrate that pregnancies among PHIVYA women were no greater than among PHEU women.49,55,57 Among partners of young men with PHIV, a higher proportion of pregnancies resulted in the birth of a child, and more PHIVYA men (7 of 16; 44%) compared with PHEUYA men (0 of 4; 0%) were living with their child. It is possible that surviving childhood with HIV motivates a desire to be involved with one’s children and that financial subsidies provided to PHIVYAs in NYC enable more child support.

Achievement of adult milestones was also mixed, with few differences by HIV status seen. Almost all reported romantic relationships, with few being married, which corresponds with national data for this age group.48 Two-thirds had received an HS diploma or the equivalent, but only 19% were in college.58 High rates of incarceration (12%) and homelessness (16%) were reported, reflecting the challenges faced by many YAs in poor, urban communities.59 

There are several limitations of our study. Our findings may not be broadly generalizable because we only included NYC participants. However, we believe that the participants are representative of PHIVYAs and PHEUYAs because NYC has been an epicenter for the US perinatal HIV epidemic, participants were recruited from 4 large HIV centers, recruitment criteria were broad, and the enrollment of eligible subjects was high (77%).23 In addition, demographics from CASAH participants correspond with those of several national studies of populations from across the United States, in which the majority of youth with PHIV and PHEU come from inner-city families whose lives were impacted by poverty and substance use, with similar sociodemographic milieus and family contexts.18,40,60 Another limitation of this analysis is that CD4+ and VL data were missing for 17% and ART regimen data were missing for 13% of participants with PHIV. Additionally, we do not have data on drug resistance. Also, there was some participant attrition from enrollment, although 75% were retained for 10 to 14 years, and we found few differences on key enrollment characteristics between those who did and did not complete FU 5, thus limiting attrition bias. Counter to expectation, those YAs without a psychiatric diagnosis were less likely to continue in both groups, but the effect was only significant among PHEU patients.23 This finding, in combination with PHIVYAs having higher rates of treatment, may have masked a mental health vulnerability of PHIVYAs. Finally, the absence of an HIV-unexposed cohort in this study limits our ability to fully discern the impact of HIV on the health outcomes of PHEUYAs and PHIVYAs.

CASAH represents 1 of the few longitudinal studies in which researchers assess health, behavioral health, and psychosocial outcomes of PHIVYAs. Many are successfully achieving YA milestones and positive health outcomes despite inherent socioeconomic and psychosocial challenges. However, high rates of psychiatric disorders, SUDs, and cognitive problems may place many PHIVYAs at risk for poor long-term outcomes. Although we found few group differences, the range of psychosocial problems in the context of PHIV can lead to devastating consequences. Given the staggering numbers of PHIVYAs worldwide, our findings reveal a critical need for integrated mental health, substance use, and health services for HIV-affected populations.61 With our findings, we also draw attention to the growing population of PHEUYAs that warrants similarly urgent opportunities for prevention and treatment.

ACASI

audio computer-assisted self-interview

ART

antiretroviral treatment

bPI

boosted protease inhibitor

CASAH

Child and Adolescent Self-Awareness and Health Study

FU

follow-up

HS

high school

NYC

New York City

PHEU

perinatally HIV–exposed but uninfected

PHEUYA

perinatally HIV–exposed but uninfected young adult

PHIV

perinatally acquired HIV infection

PHIVYA

young adult living with perinatally acquired HIV infection

STI

sexually transmitted infection

SUD

substance use disorder

TMT

Trail Making Test

VL

viral load

VS

viral suppression

YA

young adult

Drs Abrams and Mellins conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript; Ms Bucek coordinated and supervised data collection, drafted portions of the initial manuscript, and reviewed and revised the manuscript; Dr Dolezal conducted the initial analyses and reviewed and revised the manuscript; Ms Raymond collected data, coordinated and supervised data collection, and reviewed and revised the manuscript; Dr Leu interpreted data and reviewed and revised the manuscript; Drs Wiznia, Bamji, and Ng and Ms Jurgrau facilitated data acquisition and critically reviewed the manuscript for important medical and intellectual content; and all authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

FUNDING: Supported by National Institute of Mental Health grant R01-MH069133 (principal investigator: Dr Mellins) and National Institute of Mental Health center grant P30-MH43520. Funded by the National Institutes of Health (NIH).

1
Mofenson
LM
.
Prevention of mother-to-child HIV transmission: can we meet the goal of global elimination of new pediatric infections?
Curr Opin HIV AIDS
.
2013
;
8
(
5
):
443
446
[PubMed]
2
Taylor
AW
,
Nesheim
SR
,
Zhang
X
, et al
.
Estimated perinatal HIV infection among infants born in the United States, 2002-2013.
JAMA Pediatr
.
2017
;
171
(
5
):
435
442
[PubMed]
3
Centers for Disease Control and Prevention
. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 dependent areas. HIV surveillance supplemental report. 2016. Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-21-4.pdf. Accessed January 4, 2018
4
New York City Department of Health and Mental Hygiene
. Perinatal HIV in New York City, 2016. 2017. Available at: http://www1.nyc.gov/assets/doh/downloads/pdf/dires/hiv-in-peds.pdf. Accessed January 4, 2018
5
Gortmaker
SL
,
Hughes
M
,
Cervia
J
, et al;
Pediatric AIDS Clinical Trials Group Protocol 219 Team
.
Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.
N Engl J Med
.
2001
;
345
(
21
):
1522
1528
[PubMed]
6
Gona
P
,
Van Dyke
RB
,
Williams
PL
, et al
.
Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
JAMA
.
2006
;
296
(
3
):
292
300
[PubMed]
7
Mirani
G
,
Williams
PL
,
Chernoff
M
, et al;
IMPAACT P1074 Study Team
.
Changing trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy.
Clin Infect Dis
.
2015
;
61
(
12
):
1850
1861
[PubMed]
8
Neilan
AM
,
Karalius
B
,
Patel
K
, et al;
Pediatric HIV/AIDS Cohort Study
;
International Maternal Adolescent and Pediatric AIDS Clinical Trials Network
.
Association of risk of viremia, immunosuppression, serious clinical events, and mortality with increasing age in perinatally human immunodeficiency virus-infected youth.
JAMA Pediatr
.
2017
;
171
(
5
):
450
460
[PubMed]
9
Center for Disease Control and Prevention
;
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention
. Pediatric HIV surveillance. Available at: https://www.cdc.gov/hiv/pdf/library/slidesets/cdc-hiv-surveillance-pediatric.pdf. Accessed January 19, 2018
10
Xia
Q
,
Shah
D
,
Gill
B
,
Torian
LV
,
Braunstein
SL
.
Continuum of care among people living with perinatally acquired HIV infection in New York City, 2014.
Public Health Rep
.
2016
;
131
(
4
):
566
573
[PubMed]
11
Agwu
AL
,
Fairlie
L
.
Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents.
J Int AIDS Soc
.
2013
;
16
:
18579
[PubMed]
12
Fish
R
,
Judd
A
,
Jungmann
E
,
O’Leary
C
,
Foster
C
;
HIV Young Persons Network (HYPNet)
.
Mortality in perinatally HIV-infected young people in England following transition to adult care: an HIV Young Persons Network (HYPNet) audit.
HIV Med
.
2014
;
15
(
4
):
239
244
[PubMed]
13
Kahana
SY
,
Fernandez
MI
,
Wilson
PA
, et al
.
Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.
J Acquir Immune Defic Syndr
.
2015
;
68
(
2
):
169
177
[PubMed]
14
Kim
SH
,
Gerver
SM
,
Fidler
S
,
Ward
H
.
Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis.
AIDS
.
2014
;
28
(
13
):
1945
1956
[PubMed]
15
Mellins
CA
,
Malee
KM
.
Understanding the mental health of youth living with perinatal HIV infection: lessons learned and current challenges.
J Int AIDS Soc
.
2013
;
16
:
18593
[PubMed]
16
Smith
R
,
Wilkins
M
.
Perinatally acquired HIV infection: long-term neuropsychological consequences and challenges ahead.
Child Neuropsychol
.
2015
;
21
(
2
):
234
268
[PubMed]
17
Malee
KM
,
Smith
RA
,
Mellins
CA
;
Pediatric HIV/AIDS Cohort Study
.
Brain and cognitive development among U.S. youth with perinatally acquired human immunodeficiency virus infection.
J Pediatric Infect Dis Soc
.
2016
;
5
(
suppl 1
):
S1
S5
18
Smith
R
,
Chernoff
M
,
Williams
PL
, et al;
Pediatric HIV/AIDS Cohort Study (PHACS) Team
.
Impact of HIV severity on cognitive and adaptive functioning during childhood and adolescence.
Pediatr Infect Dis J
.
2012
;
31
(
6
):
592
598
[PubMed]
19
Crowell
CS
,
Malee
KM
,
Yogev
R
,
Muller
WJ
.
Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.
Rev Med Virol
.
2014
;
24
(
5
):
316
331
[PubMed]
20
Lewis-de los Angeles
CP
,
Alpert
KI
,
Williams
PL
, et al
.
Deformed subcortical structures are related to past HIV disease severity in youth with perinatally acquired HIV infection.
J Pediatric Infect Dis Soc
.
2016
;
5
(
suppl 1
):
S6
S14
21
Hoare
J
,
Fouche
JP
,
Phillips
N
, et al
.
Clinical associations of white matter damage in cART-treated HIV-positive children in South Africa.
J Neurovirol
.
2015
;
21
(
2
):
120
128
[PubMed]
22
Kang
E
,
Mellins
CA
,
Dolezal
C
,
Elkington
KS
,
Abrams
EJ
.
Disadvantaged neighborhood influences on depression and anxiety in youth with perinatally acquired human immunodeficiency virus: how life stressors matter.
J Community Psychol
.
2011
;
39
(
8
):
956
971
[PubMed]
23
Mellins
CA
,
Brackis-Cott
E
,
Leu
CS
, et al
.
Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters.
J Child Psychol Psychiatry
.
2009
;
50
(
9
):
1131
1138
[PubMed]
24
Mellins
CA
,
Elkington
KS
,
Bauermeister
JA
, et al
.
Sexual and drug use behavior in perinatally HIV-infected youth: mental health and family influences.
J Am Acad Child Adolesc Psychiatry
.
2009
;
48
(
8
):
810
819
[PubMed]
25
Elkington
KS
,
Bauermeister
JA
,
Brackis-Cott
E
,
Dolezal
C
,
Mellins
CA
.
Substance use and sexual risk behaviors in perinatally human immunodeficiency virus-exposed youth: roles of caregivers, peers and HIV status.
J Adolesc Health
.
2009
;
45
(
2
):
133
141
[PubMed]
26
Shaffer
D
,
Fisher
P
,
Dulcan
MK
, et al
.
The NIMH Diagnostic Interview Schedule for Children version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study.
J Am Acad Child Adolesc Psychiatry
.
1996
;
35
(
7
):
865
877
[PubMed]
27
Shaffer
D
,
Fisher
P
,
Lucas
CP
,
Dulcan
MK
,
Schwab-Stone
ME
.
NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses.
J Am Acad Child Adolesc Psychiatry
.
2000
;
39
(
1
):
28
38
[PubMed]
28
American Psychiatric Association
.
Diagnostic and Statistical Manual of Mental Disorders
. 4th ed.
Washington, DC
:
American Psychiatric Association
;
1994
29
Reitan
RM
.
Trail Making Test: Manual for Administration and Scoring
.
Tucson, AZ
:
Reitan Neuropsychology Laboratory
;
1992
30
Wechsler
D
.
Manual for the Wechsler Adult Intelligence Scale
.
Oxford, United Kingdom
:
Psychological Corporation
;
1955
31
Dolezal
C
,
Marhefka
SL
,
Santamaria
EK
,
Leu
CS
,
Brackis-Cott
E
,
Mellins
CA
.
A comparison of audio computer-assisted self-interviews to face-to-face interviews of sexual behavior among perinatally HIV-exposed youth.
Arch Sex Behav
.
2012
;
41
(
2
):
401
410
[PubMed]
32
Dolezal
C
,
Warne
P
,
Santamaria
EK
,
Elkington
KS
,
Benavides
JM
,
Mellins
CA
.
Asking only “did you use a condom?” underestimates the prevalence of unprotected sex among perinatally HIV infected and perinatally exposed but uninfected youth.
J Sex Res
.
2014
;
51
(
5
):
599
604
[PubMed]
33
Meyer-Bahlburg
HF
,
Ehrhardt
AA
,
Exner
TM
,
Gruen
RS
,
Dugan
T
.
Sexual Risk Behavior Assessment Schedule: Youth, 1995 Edition
.
New York, NY
:
Columbia University
;
1995
34
Johnstone
L
,
Bachman
J
,
O’Malley
P
.
Monitoring the Future: A Continuing Study of the Lifestyle and Values of Youth
.
Ann Arbor, MI
:
Institute for Social Research, University of Michigan
;
1992
35
Morton
MH
,
Dworsky
A
,
Matjasko
JL
, et al
.
Prevalence and correlates of youth homelessness in the United States.
J Adolesc Health
.
2018
;
62
(
1
):
14
21
[PubMed]
36
Gold
R
,
Kennedy
B
,
Connell
F
,
Kawachi
I
.
Teen births, income inequality, and social capital: developing an understanding of the causal pathway.
Health Place
.
2002
;
8
(
2
):
77
83
[PubMed]
37
Ann Carson
E
.
Prisoners in 2016
.
Washington, DC
:
US Bureau of Justice Statistics
;
2018
. Available at: https://www.bjs.gov/content/pub/pdf/p16.pdf. Accessed February 19, 2018
38
Usitalo
A
,
Leister
E
,
Tassiopoulos
K
, et al
.
Relationship between viral load and self-report measures of medication adherence among youth with perinatal HIV infection.
AIDS Care
.
2014
;
26
(
1
):
107
115
[PubMed]
39
Evans
SD
,
Mellins
CA
,
Leu
CS
, et al
.
HIV treatment adherence measurement and reporting concordance in youth with perinatally acquired HIV infection and their caregivers.
AIDS Patient Care STDS
.
2015
;
29
(
1
):
43
51
[PubMed]
40
Tassiopoulos
K
,
Moscicki
AB
,
Mellins
C
, et al;
Pediatric HIV/AIDS Cohort Study
.
Sexual risk behavior among youth with perinatal HIV infection in the United States: predictors and implications for intervention development.
Clin Infect Dis
.
2013
;
56
(
2
):
283
290
[PubMed]
41
Mellins
CA
,
Elkington
KS
,
Leu
CS
, et al
.
Prevalence and change in psychiatric disorders among perinatally HIV-infected and HIV-exposed youth.
AIDS Care
.
2012
;
24
(
8
):
953
962
[PubMed]
42
Kacanek
D
,
Angelidou
K
,
Williams
PL
,
Chernoff
M
,
Gadow
KD
,
Nachman
S
;
International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1055 Study Team
.
Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study.
AIDS
.
2015
;
29
(
10
):
1227
1237
[PubMed]
43
Eisenberg
D
,
Hunt
J
,
Speer
N
.
Mental health in American colleges and universities: variation across student subgroups and across campuses.
J Nerv Ment Dis
.
2013
;
201
(
1
):
60
67
[PubMed]
44
Kessler
RC
,
Avenevoli
S
,
Costello
EJ
, et al
.
Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the national comorbidity survey replication adolescent supplement.
Arch Gen Psychiatry
.
2012
;
69
(
4
):
372
380
[PubMed]
45
Substance Abuse and Mental Health Services Administration
. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). 2016. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.pdf. Accessed February 18, 2018
46
Mojtabai
R
,
Olfson
M
,
Han
B
.
National trends in the prevalence and treatment of depression in adolescents and young adults.
Pediatrics
.
2016
;
138
(
6
):
e20161878
[PubMed]
47
American College Health Association
. American College Health Association National College Health Assessment reference group executive summary spring 2017. Available at: www.acha-ncha.org/docs/NCHA-II_SPRING_2017_REFERENCE_GROUP_EXECUTIVE_SUMMARY.pdf. Accessed February 18, 2018
48
Federal Interagency Forum on Child and Family Statistics
. America’s young adults: special issue, 2014. 2014. Available at: https://www.childstats.gov/pdf/ac2014/YA_14.pdf. Accessed February 18, 2018
49
Fernández
MI
,
Huszti
HC
,
Wilson
PA
, et al
.
Profiles of risk among HIV-infected youth in clinic settings.
AIDS Behav
.
2015
;
19
(
5
):
918
930
[PubMed]
50
Elkington
KS
,
Cruz
JE
,
Warne
P
,
Santamaria
EK
,
Dolezal
C
,
Mellins
CA
.
Marijuana use and psychiatric disorders in perinatally HIV-exposed youth: does HIV matter?
J Pediatr Psychol
.
2016
;
41
(
3
):
277
286
[PubMed]
51
Bucek
A
,
Leu
CS
,
Benson
S
, et al
.
Psychiatric disorders, antiretroviral medication adherence and viremia in a cohort of perinatally HIV-infected adolescents and young adults.
Pediatr Infect Dis J
.
2018
.
37
(
7
):
673
677
52
Judd
A
,
Le Prevost
M
,
Melvin
D
, et al;
Adolescents and Adults Living With Perinatal HIV (AALPHI) Steering Committee
.
Cognitive function in young persons with and without perinatal HIV in the AALPHI cohort in England: role of non-HIV-related factors.
Clin Infect Dis
.
2016
;
63
(
10
):
1380
1387
[PubMed]
53
Phillips
N
,
Amos
T
,
Kuo
C
, et al
.
HIV-associated cognitive impairment in perinatally infected children: a meta-analysis.
Pediatrics
.
2016
;
138
(
5
):
e20160893
[PubMed]
54
Weber
E
,
Blackstone
K
,
Woods
SP
.
Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action.
Neuropsychol Rev
.
2013
;
23
(
1
):
81
98
[PubMed]
55
Prieto
LM
,
Fernández McPhee
C
,
Rojas
P
, et al;
Madrid Cohort of HIV-Infected Mother-Infant Pairs
.
Pregnancy outcomes in perinatally HIV-infected young women in Madrid, Spain: 2000-2015.
PLoS One
.
2017
;
12
(
8
):
e0183558
56
Calitri
C
,
Gabiano
C
,
Galli
L
, et al;
Italian Register for HIV Infection in Children
.
The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infection.
BMC Infect Dis
.
2014
;
14
:
277
[PubMed]
57
Byrne
L
,
Sconza
R
,
Foster
C
,
Tookey
PA
,
Cortina-Borja
M
,
Thorne
C
.
Pregnancy incidence and outcomes in women with perinatal HIV infection.
AIDS
.
2017
;
31
(
12
):
1745
1754
[PubMed]
58
Vuppula
S
,
Tyungu
D
,
Kaul
A
,
Chandwani
S
,
Rigaud
M
,
Borkowsky
W
.
Thirty-year perspective of the long-term survival, CD4 percentage and social achievements of perinatally HIV-infected children as a function of their birth era.
Pediatr Infect Dis J
.
2017
;
36
(
2
):
198
201
[PubMed]
59
Elkington
KS
,
Peters
Z
,
Choi
CJ
, et al
.
Predicting arrest in a sample of youth perinatally exposed to HIV: the intersection of HIV and key contextual factors [published online ahead of print November 22, 2017].
AIDS Behav
. doi:
[PubMed]
60
Gadow
KD
,
Angelidou
K
,
Chernoff
M
, et al
.
Longitudinal study of emerging mental health concerns in youth perinatally infected with HIV and peer comparisons.
J Dev Behav Pediatr
.
2012
;
33
(
6
):
456
468
[PubMed]
61
Substance Abuse and Mental Health Services Administration
;
Health Resources and Services Administration
. The case for behavioral health screening in HIV care settings. 2016. Available at: https://store.samhsa.gov/shin/content/SMA16-4999/SMA16-4999.pdf. Accessed February 18, 2018

Competing Interests

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest relevant to this article to disclose.

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

Supplementary data